{"entity":{"id":"luminosity","kind":"trial","name":"LUMINOSITY","aka":[],"tldr":"The single-arm study behind the first c-Met-directed antibody-drug conjugate approval in lung cancer: tumours shrank in about a third of patients whose cancers carried high c-Met protein, with eye and nerve side effects to watch.","summary":"LUMINOSITY, trial NCT03539536 sponsored by AbbVie and published in the Journal of Clinical Oncology in 2024, gave telisotuzumab vedotin to previously treated patients with non-squamous, EGFR wild-type non-small-cell lung cancer whose tumours overexpressed c-Met protein on immunohistochemistry. The objective response rate was 28.6% overall, 34.6% in the c-Met high group and 22.9% in the intermediate group, with peripheral sensory neuropathy, peripheral oedema and keratitis among the notable side effects. The c-Met high results supported the 2025 US accelerated approval of Emrelis, the first c-Met-directed ADC in lung cancer; the confirmatory phase 3 trial TeliMET NSCLC-01 is ongoing.","status":"positive","asOf":"2026-09-04","links":[{"label":"ClinicalTrials.gov NCT03539536","url":"https://clinicaltrials.gov/study/NCT03539536"},{"label":"Camidge et al., Telisotuzumab vedotin monotherapy in previously treated c-Met protein-overexpressing non-squamous NSCLC: LUMINOSITY (Journal of Clinical Oncology 2024)","url":"https://doi.org/10.1200/JCO.24.00720"}],"tags":[],"related":[],"cancers":["nsclc","met-altered-nsclc"],"sections":[],"technologies":["adc"],"targets":["met"],"drugs":["telisotuzumab-vedotin"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-luminosity-j-clin-oncol-2024","paper-luminosity-jto-clin-res-rep-2026-update"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03539536","phase":"2","setting":"Previously treated c-Met protein-overexpressing, EGFR wild-type non-squamous NSCLC: telisotuzumab vedotin single arm","sponsor":"AbbVie","result":"ORR 28.6% overall; 34.6% in c-Met high, 22.9% in c-Met intermediate.","started":"2018-10-10","startedType":"actual","yearReported":2024,"enrolled":270,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective response rate (independent review)","primary":true,"unit":"%","arms":[{"name":"Telisotuzumab vedotin, c-Met high","n":78,"value":34.6},{"name":"Telisotuzumab vedotin, c-Met intermediate","n":83,"value":22.9}],"source":"https://doi.org/10.1200/JCO.24.00720"}]},"route":"/trials/luminosity/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"drug":[{"id":"telisotuzumab-vedotin","kind":"drug","name":"Telisotuzumab vedotin","route":"/drugs/telisotuzumab-vedotin/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}],"paper":[{"id":"paper-luminosity-jto-clin-res-rep-2026-update","kind":"paper","name":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial","route":"/key-papers/paper-luminosity-jto-clin-res-rep-2026-update/"},{"id":"paper-luminosity-j-clin-oncol-2024","kind":"paper","name":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR -Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","route":"/key-papers/paper-luminosity-j-clin-oncol-2024/"}]}}